Baudax Bio

Baudax Bio FCF/Debt

The Free Cash Flow to Debt Ratio of Baudax Bio (BXRXQ) as of Oct 16, 2026 is -390.59 %. In the previous year, Free Cash Flow to Debt Ratio was -579.95 % — a change of -32.65% (higher).

FCF/Debt

-390.59 %

YoY

-32.65%

Last updated:

Free Cash Flow to Debt Ratio of Baudax Bio is 2022 -390.59 % . Free Cash Flow to Debt Ratio of Baudax Bio was 2021 -579.95 % . It decreases by -32.65% higher compared to the previous year.

The Baudax Bio FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2020
-488.52 USD
Jan 1, 2021
-579.95 USD
Jan 1, 2022
-390.59 USD
The Baudax Bio FCF/Debt history
YEARFCF/DebtYoY
-390.59 %-32.65%
-579.95 %+18.72%
-488.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baudax Bio Stock analysis

What does Baudax Bio do? Baudax Bio Inc, a pharmaceutical company based in Malvern, Pennsylvania, is engaged in the development and commercialization of products for hospital and acute care settings. The company, which went public via an IPO on November 14, 2019, currently employs nine full-time staff. Its lead product candidate is ANJESO injection, a cyclooxygenase-2 (COX-2) preferential non-steroidal anti-inflammatory drug designed for the management of moderate to severe pain. ANJESO may be used alone or in combination with other non-NSAID analgesics. Baudax Bio's pipeline includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, intended for use as muscle paralyzing agents during intubation and surgical procedures. The company is developing an intermediate-acting NMBA called BX-1000, an ultrashort-acting NMBA named BX-2000, and a reversal agent specific to its NMBAs. Additionally, Baudax Bio is exploring the discovery and development of Treg-based cell therapies for autoimmune diseases. The company's website is www.baudaxbio.com. Baudax Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baudax Bio stock

Free Cash Flow to Debt Ratio of Baudax Bio is -390.59 % in 2022.

Free Cash Flow to Debt Ratio of Baudax Bio changed from -579.95 % to -390.59 %, representing a -32.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Baudax Bio since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Baudax Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Baudax Bio

All Key Metrics — Baudax Bio